Review
Microbiology
Caterina Sagnelli, Laura Montella, Pierantonio Grimaldi, Mariantonietta Pisaturo, Loredana Alessio, Stefania De Pascalis, Evangelista Sagnelli, Nicola Coppola
Summary: HBV infection remains a significant public health issue globally, and patients may experience hepatitis reactivation while undergoing immunosuppressive therapy or chemotherapy; the COVID-19 pandemic has introduced new risks for HBV reactivation, especially with the use of medications like dexamethasone.
Review
Gastroenterology & Hepatology
Terry Cheuk-Fung Yip, Madeleine Gill, Grace Lai-Hung Wong, Ken Liu
Summary: There have been significant advancements in novel treatments for COVID-19, but some treatments may cause hepatitis B reactivation in patients with current or past HBV infection. The risk of HBVr exists, especially among those without antiviral prophylaxis, highlighting the importance of further research on the use of immunosuppressive therapies in COVID-19 patients with HBV infection.
HEPATOLOGY INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Takako Inoue, Shigeru Kusumoto, Etsuko Iio, Shintaro Ogawa, Takanori Suzuki, Shintaro Yagi, Atsushi Kaneko, Kentaro Matsuura, Katsumi Aoyagi, Yasuhito Tanaka
Summary: A fully automated, novel high-sensitivity hepatitis B core-related antigen assay (iTACT-HBcrAg) has been developed for monitoring chronic hepatitis B (CHB) and for the early detection of HBV reactivation. The clinical performance of iTACT-HBcrAg was compared with other HBV markers, showing satisfactory analytical performance and potential as a general marker of disease progression and treatment response.
JOURNAL OF HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Takako Inoue, Takeshi Matsui, Yasuhito Tanaka
Summary: Hepatitis B virus (HBV) reactivation can occur under systemic chemotherapy or immunosuppressive therapy, necessitating screening tests before therapy. Recent advancements in highly sensitive biomarkers have enabled early diagnosis of HBV reactivation.
HEPATOLOGY RESEARCH
(2021)
Article
Immunology
Serena Zaltron, Anna Cambianica, Marco Di Gregorio, Cosimo Colangelo, Samuele Storti, Giorgio Tiecco, Francesco Castelli, Eugenia Quiros-Roldan
Summary: We report a case of occult hepatitis B virus infection (OBI) reactivation in a HIV/HCV co-infected patient who was followed for 25 years but lost to follow-up after Direct-acting antivirals (DAAs) treatment. The patient showed severe immunosuppression and high replication of plasmatic HIV-RNA, followed by an immune reconstitution inflammatory syndrome (IRIS) with detectable HBV-DNA load and transaminase elevation after ART reintroduction. This case highlights the importance of closely monitoring HBV serological and virological markers in individuals with impaired immune systems, especially in patients on tenofovir or lamivudine-sparing regimens.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Review
Medicine, General & Internal
Cori Campbell, Monique I. Andersson, M. Azim Ansari, Olivia Moswela, Siraj A. Misbah, Paul Klenerman, Philippa C. Matthews
Summary: This study aimed to assimilate existing data for complications of TCZ therapy in severe COVID-19, revealing unintended consequences of HBV and TB with TCZ use. Due to heterogeneity in the related studies, a formal meta-analysis was not possible.
FRONTIERS IN MEDICINE
(2021)
Article
Virology
Chih-Wei Tseng, Wen-Chun Liu, Ping-Hung Ko, Yen-Chun Chen, Kuo-Chih Tseng, Ting-Tsung Chang
Summary: This study found that patients coinfected with hepatitis B and C have a potential risk of hepatitis B reactivation after direct-acting antiviral treatment. The study suggests that the hepatitis B surface antigen (HBsAg) titer can be used as a predictive factor for hepatitis B reactivation.
Article
Immunology
Xiangjuan Guo, Tongtong Ji, Shengliang Xin, Jinghang Xu, Yanyan Yu
Summary: A 72-year-old woman with isolated HBcAb positive developed HBV reactivation during R-CHOP therapy for diffuse large B-cell lymphoma. Reactivation was confirmed based on detectable HBV DNA until 19 months post-therapy, which became undetectable after TAF treatment. Regular monitoring is crucial for timely diagnosis and management of HBV reactivation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Chia Jie Tan, Rajneesh Kumar, Narendran Koomanan, Wei Sheng Loo, Mohamad Farid, Miriam Tao, Nagavalli Somasundaram, Eileen Poon, Jason Yongsheng Chan, Valerie Shiwen Yang, Esther Chang, Soon Thye Lim, Wan Cheng Chow, Alexandre Chan, Tiffany Tang
Summary: The surveillance protocol for managing HBV reactivation among lymphoma patients receiving rituximab is effective, feasible, and cost-saving, with no reactivation-related events detected in the study.
Article
Chemistry, Multidisciplinary
Chenya Zhuo, Huiming Kong, Ke Yi, Chun-Wei Chi, Jiabing Zhang, Ran Chen, Haixia Wang, Caixia Wu, Yeh-Hsing Lao, Yu Tao, Mingqiang Li
Summary: A liver-specific CRISPR/Cas9 magnetic nanosystem is developed to treat chronic hepatitis B infection. With the help of magnetic field, the system enables spatially specific distribution and hepatocyte-specific gene editing, resulting in effective inactivation of HBV genome without off-target effects.
ADVANCED FUNCTIONAL MATERIALS
(2023)
Article
Surgery
Hsin-Ju Tsai, Ming-Ju Wu, Cheng-Hsu Chen, Sheng-Shun Yang, Yi-Hsiang Huang, Yan-Zin Chang, Horng-Rong Chang, Teng-Yu Lee
Summary: This hospital-based retrospective cohort study found that the prophylaxis strategy for HBV reactivation in kidney transplant recipients with resolved HBV infection remains unclear. The absence of anti-HBs antibody and the use of high-dose steroids were identified as independent risk factors for HBV reactivation. Therefore, the strategy of HBV antiviral prophylaxis may be defined according to the risk stratification.
TRANSPLANT INTERNATIONAL
(2023)
Article
Immunology
Shida Pan, Yingying Yu, Siyu Wang, Bo Tu, Yingjuan Shen, Qin Qiu, Xiaomeng Liu, Nan Su, Yanmei Zuo, Junqing Luan, Ji-Yuan Zhang, Ming Shi, Fanping Meng, Fu-Sheng Wang
Summary: This study investigates the efficacy and safety of programmed death-1 (PD-1) immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in patients with hepatitis B virus (HBV)-related liver cancer. The combination therapy has an impact on HBV infection, and elevated levels of HBV DNA and HBsAg may indicate poorer tumor response and survival time.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Yi-Feng Wu, Wan-Jun Yu, Yu-Hua Jiang, Yin Chen, Bo Zhang, Rui-Bing Zhen, Jun-Tao Zhang, Yi-Ping Wang, Qiang Li, Feng Xu, Yan-Jun Shi, Xian-Peng Li
Summary: COVID-19 or treatment-associated immunosuppression may trigger HBV reactivation in patients with chronic hepatitis B.
WORLD JOURNAL OF CLINICAL CASES
(2021)
Article
Gastroenterology & Hepatology
Jiaqi Li, Xi Liang, Shaoli You, Tingting Feng, Xin Zhou, Bing Zhu, Jinjin Luo, Jiaojiao Xin, Jing Jiang, Dongyan Shi, Yingyan Lu, Keke Ren, Tianzhou Wu, Lingling Yang, Jiang Li, Tan Li, Qun Cai, Suwan Sun, Beibei Guo, Xingping Zhou, Jiaxian Chen, Lulu He, Peng Li, Hui Yang, Wen Hu, Zhanglu An, Xiaojun Jin, Jin Tian, Baoju Wang, Xin Chen, Shaojie Xin, Jun Li
Summary: A new prognostic score based on six predictors was developed to accurately predict short-term mortality in patients with HBV-ACLF. This score outperformed four other commonly used scores in terms of predictive ability.
JOURNAL OF HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Takanori Suzuki, Takako Inoue, Kentaro Matsuura, Shigeru Kusumoto, Shinya Hagiwara, Shintaro Ogawa, Shintaro Yagi, Atsushi Kaneko, Kei Fujiwara, Takehisa Watanabe, Katsumi Aoyagi, Yukitomo Urata, Akihiro Tamori, Hiromi Kataoka, Yasuhito Tanaka
Summary: This study evaluated the efficacy of a novel hepatitis B core-related antigen assay (iTACT-HBcrAg) in diagnosing HBV reactivation in a multi-center setting. The results showed that iTACT-HBcrAg had a high sensitivity for early detection of HBV reactivation, making it a valuable tool for initiating nucleos(t)ide analogue treatment.
JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Mathematics, Interdisciplinary Applications
Tingyan Wang, Xin Tian, Ming Yu, Xin Qi, Lan Yang
JOURNAL OF SYSTEMS SCIENCE & COMPLEXITY
(2017)
Article
Multidisciplinary Sciences
Tingyan Wang, Robin G. Qiu, Ming Yu
SCIENTIFIC REPORTS
(2018)
Article
Computer Science, Artificial Intelligence
Tingyan Wang, Robin G. Qiu, Ming Yu, Runtong Zhang
DECISION SUPPORT SYSTEMS
(2020)
Article
Computer Science, Information Systems
Tingyan Wang, Yuanxin Tian, Robin G. Qiu
IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS
(2020)
Article
Endocrinology & Metabolism
E. Erjiang, Tingyan Wang, Lan Yang, Mary Dempsey, Attracta Brennan, Ming Yu, Wing P. Chan, Bryan Whelan, Carmel Silke, Miriam O'Sullivan, Bridie Rooney, Aoife McPartland, Grainne O'Malley, John J. Carey
JOURNAL OF CLINICAL DENSITOMETRY
(2020)
Review
Gastroenterology & Hepatology
Cori Campbell, Tingyan Wang, Anna L. McNaughton, Eleanor Barnes, Philippa C. Matthews
Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer mortality globally, particularly in individuals with chronic hepatitis B virus (HBV) infection. Research shows that diabetes mellitus (DM) is significantly associated with an increased risk of HCC, emphasizing the need for enhanced screening of HBV and diabetic patients.
JOURNAL OF VIRAL HEPATITIS
(2021)
Article
Public, Environmental & Occupational Health
Tingyan Wang, David A. Smith, Cori Campbell, Oliver Freeman, Zuzana Moysova, Theresa Noble, Kinga A. Varnai, Steve Harris, Hizni Salih, Gail Roadknight, Stephanie Little, Ben Glampson, Luca Mercuri, Dimitri Papadimitriou, Christopher R. Jones, Vince Taylor, Afzal Chaudhry, Hang Phan, Florina Borca, Josune Olza, Frazer Warricker, Luis Romao, David Ramlakhan, Louise English, Paul Klenerman, Monique Andersson, Jane Collier, Alexander J. Stockdale, Stacy Todd, Karl McIntyre, Andrew Frankland, Eleni Nastouli, Salim Khakoo, William Gelson, Graham S. Cooke, Kerrie Woods, Jim Davies, Eleanor Barnes, Philippa C. Matthews
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
(2022)
Article
Rheumatology
Mina Ebrahimiarjestan, Lan Yang, E. Erjiang, Tingyan Wang, John J. Carey, Bryan Whelan, Carmel Silke, Miriam O'Sullivan, Amina Gsel, Attracta Brennan, Mary Dempsey, Ming Yu
Summary: Rheumatoid arthritis (RA) is a chronic disabling disease that affects millions of people worldwide. This study compares baseline demographic and DXA data between healthy controls, RA patients, and a non-RA cohort with major risk factors and/or prior major osteoporotic fractures (MOF). The study found that patients with previous MOF in both the RA and non-RA cohorts were older and had significantly lower BMD at multiple skeletal sites.
RHEUMATOLOGY ADVANCES IN PRACTICE
(2023)
Article
Gastroenterology & Hepatology
Tingyan Wang, David A. Smith, Cori Campbell, Steve Harris, Hizni Salih, Kinga A. Varnai, Kerrie Woods, Theresa Noble, Oliver Freeman, Zuzana Moysova, Thomas Marjot, Gwilym J. Webb, Jim Davies, Eleanor Barnes, Philippa C. Matthews
Summary: In this study involving hospitalized patients in the United Kingdom, abnormal liver biochemistry, especially hypoalbuminemia and rising alkaline phosphatase over time, were common in COVID-19 patients and could serve as prognostic markers for death. Further investigation in larger cohorts is necessary for a better understanding of the relationship between liver biochemistry and disease outcomes.
HEPATOLOGY COMMUNICATIONS
(2021)